Natriuretic peptides, in particular, brain or B-type, are useful for the assessment of patients presenting with dyspnea to the medical office or emergency department. Levels of natriuretic peptides are useful for assessing prognosis of heart failure or coronary syndrome patients. Less is known about serial peptide measurements for guiding treatment strategies in heart failure. The authors review the uses, pitfalls, and practical points for using natriuretic peptides clinically.
Valli N., Gobinet A., Bordenave L.Review of ten years of the clinical use of brain natriuretic peptide in cardiology . J Lab Clin Med.1999;134:437-444.
2.
Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350:1349-1353.
3.
Maisel AS, Krishnaswamy P., Nowak RM, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med.2002; 347:161-167.
4.
McCullough PA , Nowak RM, McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002; 106:416-422.
5.
Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of heart failure: executive summary (update 2005). Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J.2005;26:1115-1140.
6.
Yamamoto K., Burnett JC, Bermudez EA, et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000 ;6:194-200.
7.
McDonagh TA, Robb SD, Morton JJ, et al. Biochemical detection of left ventricular systolic dysfunction . Lancet. 1998;351:9-13.
8.
Januzzi JL, Camargo CA, Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol.2005 ;15;95:948-954.
9.
Hall C. Essentialbiochemistry and physiology of (NTpro)BNP. Eur J Heart Fail. 2004;6:257-260.
10.
Doust JA, Glasziou PP, Pietrzak E., Dobson AJA systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med.2004; 164:1978-1984.
11.
Gwechenberger M., Huelsmann M., Graf S., et al. Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers. Eur J Clin Invest.2004;34:811-817.
12.
Hermann-Arnhof KM, Hanusch-Enserer U., Kaestenbauer T., et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem.2005;51:138-143.
Roongsritong C., Qaddour A., Cox SL, Labib S., Bradley CABrain natriuretic peptide and diastolic dysfunction in the elderly: influence of gender. Congest Heart Fail. 2005;11:65-67.
15.
Rivera M., Cortes R., Salvador A., et al. Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology. Eur J Heart Fail. 2005;7:1168-1170.
16.
Lainchbury JG, Campbell E., Frampton CM, et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol.2003; 42:728-735.
17.
Mueller T., Gegenhuber A., Poelz W., Haltmayer M.Biochemical diagnosis of impaired left ventricular ejection fraction—comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med.2004 ;42:159-163.
18.
Vanderheyden M., Bartunek J., Goethals M.Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;6:261-268.
19.
Mair J.Monitoring of patients with heart failure. Scan J Clin Lab Invest Suppl. 2005;240:99-106.
20.
Yeo KT, Wu Ahb, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338: 107-115.
21.
Sokoll LJ, Baum H., Collinson PO, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med.2004;42:965-972.
22.
Wu AH, Packer M., Smith A., et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem.2004;50:867-873.
23.
Rawlins ML, Owen WE, Roberts WLPerformance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol.2005;123:439-445.
24.
Richards AM , Troughton R., Lainchbury J., et al. Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies. J Card Fail. 2005;11(suppl 5):S34-S37.
25.
Bettencourt P., Frioes F., Azevedo A., et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol.2004;93:45-48.
26.
Murdoch DR, McDonagh TA, Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy . Am Heart J.1999;138(pt 1):1126-1132.
27.
Troughton RW , Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
28.
Davis ME, Richards AM, Nicholls MG, et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation. 2006; 113:977-985.
29.
Yoshizawa A., Yoshikawa T., Nakamura I., et al. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. J Card Fail. 2004;10:310-315.
30.
Marie PY, Mertes PM, Hassan-Sebbag N., et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol.2004;43:353-359.
31.
Olsen MH, Wachtell K., Tuxen C., et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy . J Hypertens.2005;23: 1083-1090.
